

Welcome to STN International! Enter x:x

LOGINID:sssptal653rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	32	JUN 30	STN on the Web enhanced with new STN AnaVist

Assistant and BLAST plug-in
NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:53:02 ON 11 JUL 2008

=> file medline biosis embase uspatfull caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 08:53:32 ON 11 JUL 2008

FILE 'BIOSIS' ENTERED AT 08:53:32 ON 11 JUL 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 08:53:32 ON 11 JUL 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 08:53:32 ON 11 JUL 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 08:53:32 ON 11 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s leuprorelin
L1 7580 LEUPRORELIN

=> l1 and (leuprorelin acetate)
L1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l1 and (leuprorelin acetate)
L2 855 L1 AND (LEUPRORELIN ACETATE)

=> s l2 and (GnRH and LHRH)
L3 43 L2 AND (GNRH AND LHRH)

=> s l3 and (goserelin or buserelin)
L4 29 L3 AND (GOSERELIN OR BUSERELIN)

=> s 14 and (time released or sustained release)
L5 24 L4 AND (TIME RELEASED OR SUSTAINED RELEASE)

=> s 15 and (microcapsule#)
L6 7 L5 AND (MICROCAPSULE#)

=> dup rem 15
PROCESSING COMPLETED FOR L5
L7 24 DUP REM L5 (0 DUPLICATES REMOVED)

=> d 15 1-24

L5 ANSWER 1 OF 24 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 1993:99535 BIOSIS
DN PREV199395054731
TI Endocrinological study with leuprorelin acetate
sustained release injection (TAP-144-SR) in
endometriosis.
AU Uemura, Tsuguo [Reprint author]; Shirasu, Kazuhiro [Reprint author]; Hori,
Hiromasa [Reprint author]; Ooyama, Toshiki [Reprint author]; Onose, Ryou
[Reprint author]; Ishikawa, Masahiko [Reprint author]; Tsuchiya, Shinichi
[Reprint author]; Minaguchi, Hiroshi [Reprint author]; Osada, Hisafumi
CS Dep. Obstetrics and Gynecol., Yokohama City Univ. Sch. Med., Yokohama 236,
Japan
SO Japanese Journal of Fertility and Sterility, (1992) Vol. 37, No. 4, pp.
12-19.
CODEN: NFGZAD. ISSN: 0029-0629.
DT Article
LA Japanese
ED Entered STN: 9 Feb 1993
Last Updated on STN: 10 Feb 1993

L5 ANSWER 2 OF 24 USPATFULL on STN
AN 2008:159020 USPATFULL
TI REMEDIES FOR SEX HORMONE DEPENDENT DISEASE
IN Hara, Takahito, Osaka, JAPAN
Kusaka, Masami, Kobe-shi, JAPAN
PA Takeda Pharmaceutical Company Limited (non-U.S. corporation)
PI US 20080138426 A1 20080612
AI US 2007-864022 A1 20070928 (11)
RLI Continuation of Ser. No. US 2004-507044, filed on 9 Sep 2004, ABANDONED
A 371 of International Ser. No. WO 2003-JP2783, filed on 10 Mar 2003
PRAI JP 2002-65734 20020311
DT Utility
FS APPLICATION
LN.CNT 2184
INCL INCLM: 424/490.000
INCLS: 514/171.000; 514/169.000
NCL NCLM: 424/490.000
NCLS: 514/171.000; 514/169.000
IC IPCI A61K0031-56 [I,A]; A61K0009-50 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 24 USPATFULL on STN
AN 2008:36518 USPATFULL
TI Bioimplant formulation
IN Trigg, Timothy Elliott, Warrawee, AUSTRALIA
Walsh, John Desmond, Curl Curl, AUSTRALIA
Rathjen, Deborah Ann, Flagstaff Hill, AUSTRALIA
PA Peptech Limited, North Ryde, AUSTRALIA (non-U.S. corporation)

PI US 20080031956 A1 20080207
 AI US 2007-727655 A1 20070327 (11)
 RLI Continuation-in-part of Ser. No. US 2005-41270, filed on 25 Jan 2005,
 ABANDONED Continuation of Ser. No. US 2001-743059, filed on 12 Feb 2001,
 GRANTED, Pat. No. US 6913761 A 371 of International Ser. No. WO
 1999-AU585, filed on 20 Jul 1999
 PRAI AU 1998-4730 19980720
 AU 1998-4731 19980720
 AU 1999-324 19990513
 DT Utility
 FS APPLICATION
 LN.CNT 825
 INCL INCLM: 424/489.000
 INCLS: 514/012.000; 514/015.000; 514/002.000; 514/263.100; 514/321.000;
 514/044.000; 514/789.000; 514/009.000
 NCL NCLM: 424/489.000
 NCLS: 514/002.000; 514/009.000; 514/012.000; 514/015.000; 514/044.000;
 514/263.100; 514/321.000; 514/789.000
 IC IPCI A61K0009-14 [I,A]; A61K0031-4523 [I,A]; A61K0031-52 [I,A];
 A61K0031-519 [I,C*]; A61K0031-7052 [I,A]; A61K0031-7042 [I,C*];
 A61P0043-00 [I,A]; A61K0038-08 [I,A]; A61K0038-13 [I,A];
 A61K0038-12 [I,C*]; A61K0038-16 [I,A]
 IPCR A61K0009-14 [I,C]; A61K0009-14 [I,A]; A61K0031-4523 [I,C];
 A61K0031-4523 [I,A]; A61K0031-519 [I,C]; A61K0031-52 [I,A];
 A61K0031-7042 [I,C]; A61K0031-7052 [I,A]; A61K0038-08 [I,C];
 A61K0038-08 [I,A]; A61K0038-12 [I,C]; A61K0038-13 [I,A];
 A61K0038-16 [I,C]; A61K0038-16 [I,A]; A61P0043-00 [I,C];
 A61P0043-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 24 USPATFULL on STN
 AN 2007:198108 USPATFULL
 TI Methods for slowing senescence and treating and preventing diseases
 associated with senescence
 IN Bowen, Richard L., Raleigh, NC, UNITED STATES
 PA Voyager Pharmaceutical Corporation, Raleigh, NC, UNITED STATES (U.S.
 corporation)
 PI US 20070173454 A1 20070726
 AI US 2007-709837 A1 20070223 (11)
 RLI Continuation of Ser. No. US 2002-321579, filed on 18 Dec 2002, ABANDONED
 PRAI US 2001-340502P 20011219 (60)
 US 2002-385577P 20020605 (60)
 US 2002-369857P 20020405 (60)
 US 2002-385576P 20020605 (60)
 US 2002-383624P 20020529 (60)
 US 2002-385560P 20020605 (60)
 US 2002-385559P 20020605 (60)
 US 2002-385561P 20020605 (60)
 US 2002-385575P 20020605 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1965
 INCL INCLM: 514/012.000
 INCLS: 514/015.000
 NCL NCLM: 514/012.000
 NCLS: 514/015.000
 IC IPCI A61K0038-23 [I,A]; A61K0038-09 [I,A]; A61K0038-08 [I,C*]
 IPCR A61K0038-23 [I,C]; A61K0038-23 [I,A]; A61K0031-00 [I,C*];
 A61K0031-00 [I,A]; A61K0031-045 [I,C*]; A61K0031-07 [I,A];
 A61K0031-165 [I,C*]; A61K0031-165 [I,A]; A61K0031-17 [I,C*];
 A61K0031-17 [I,A]; A61K0031-337 [I,C*]; A61K0031-337 [I,A];

A61K0038-08 [I,C]; A61K0038-09 [I,A]; A61K0038-24 [I,C*];
A61K0038-24 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 24 USPATFULL on STN
AN 2006:334667 USPATFULL
TI Compositions comprising a SARM ad GnRH agonist or a
GnRH antagonist, and methods of use thereof
IN Steiner, Mitchell S., Germantown, TN, UNITED STATES
Veverka, Karen A., Cordova, TN, UNITED STATES
PI US 20060287282 A1 20061221
AI US 2004-3938 A1 20041206 (11)
RLI Continuation-in-part of Ser. No. US 2002-270232, filed on 15 Oct 2002,
GRANTED, Pat. No. US 6838484 Continuation-in-part of Ser. No. US
2001-935044, filed on 23 Aug 2001, GRANTED, Pat. No. US 6492554
Continuation-in-part of Ser. No. US 2001-935045, filed on 23 Aug 2001,
GRANTED, Pat. No. US 6569896
PRAI US 2001-300083P 20010625 (60)
DT Utility
FS APPLICATION
LN.CNT 2019
INCL INCLM: 514/114.000
INCLS: 514/617.000; 514/618.000; 514/620.000; 514/493.000; 514/522.000;
514/616.000; 514/599.000; 514/357.000; 514/400.000; 514/184.000
NCL NCLM: 514/114.000
NCLS: 514/184.000; 514/357.000; 514/400.000; 514/493.000; 514/522.000;
514/599.000; 514/616.000; 514/617.000; 514/618.000; 514/620.000
IC IPCI A61K0031-675 [I,A]; A61K0031-555 [I,A]; A61K0031-277 [I,A];
A61K0031-275 [I,C*]; A61K0031-32 [I,A]; A61K0031-28 [I,C*];
A61K0031-165 [I,A]
IPCR A61K0031-675 [I,C]; A61K0031-675 [I,A]; A61K0031-165 [I,C];
A61K0031-165 [I,A]; A61K0031-275 [I,C]; A61K0031-277 [I,A];
A61K0031-28 [I,C]; A61K0031-32 [I,A]; A61K0031-555 [I,C];
A61K0031-555 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 24 USPATFULL on STN
AN 2006:125332 USPATFULL
TI Fused benzene derivative and use
IN Shiraishi, Mitsuru, Hyogo, JAPAN
Hara, Takahito, Los Angeles, CA, UNITED STATES
Kusaka, Masami, Hyogo, JAPAN
Kanzaki, Naoyuki, Osaka, JAPAN
Yamamoto, Satoshi, Osaka, JAPAN
Miyawaki, Toshio, Hyogo, JAPAN
PI US 20060106067 A1 20060518
AI US 2003-524452 A1 20030811 (10)
WO 2003-JP10228 20030811
20050829 PCT 371 date
PRAI JP 2002-235275 20020812
DT Utility
FS APPLICATION
LN.CNT 8660
INCL INCLM: 514/320.000
INCLS: 546/195.000
NCL NCLM: 514/320.000
NCLS: 546/195.000
IC IPCI A61K0031-454 [I,A]; A61K0031-4523 [I,C*]; C07D0409-02 [I,A];
C07D0409-00 [I,C*]
IPCR A61K0031-4523 [I,C]; A61K0031-454 [I,A]; A61P0005-00 [I,C*];
A61P0005-26 [I,A]; A61P0013-00 [I,C*]; A61P0013-08 [I,A];

A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0015-10 [I,A];
 A61P0015-12 [I,A]; A61P0019-00 [I,C*]; A61P0019-10 [I,A];
 A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*];
 A61P0043-00 [I,A]; C07C0035-00 [I,C*]; C07C0035-52 [I,A];
 C07C0217-00 [I,C*]; C07C0217-04 [I,A]; C07C0255-00 [I,C*];
 C07C0255-52 [I,A]; C07C0255-53 [I,A]; C07C0255-54 [I,A];
 C07C0255-56 [I,A]; C07D0207-00 [I,C*]; C07D0207-06 [I,A];
 C07D0207-08 [I,A]; C07D0207-10 [I,A]; C07D0207-12 [I,A];
 C07D0207-14 [I,A]; C07D0207-16 [I,A]; C07D0207-22 [I,A];
 C07D0207-24 [I,A]; C07D0209-00 [I,C*]; C07D0209-46 [I,A];
 C07D0211-00 [I,C*]; C07D0211-22 [I,A]; C07D0211-28 [I,A];
 C07D0211-34 [I,A]; C07D0211-42 [I,A]; C07D0211-46 [I,A];
 C07D0211-60 [I,A]; C07D0211-62 [I,A]; C07D0211-74 [I,A];
 C07D0231-00 [I,C*]; C07D0231-08 [I,A]; C07D0261-00 [I,C*];
 C07D0261-04 [I,A]; C07D0265-00 [I,C*]; C07D0265-02 [I,A];
 C07D0267-00 [I,C*]; C07D0267-10 [I,A]; C07D0295-00 [I,C*];
 C07D0295-073 [I,A]; C07D0295-112 [I,A]; C07D0295-155 [I,A];
 C07D0303-00 [I,C*]; C07D0303-46 [I,A]; C07D0307-00 [I,C*];
 C07D0307-79 [I,A]; C07D0333-00 [I,C*]; C07D0333-54 [I,A];
 C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0409-00 [I,C];
 C07D0409-02 [I,A]; C07D0409-04 [I,A]; C07D0491-00 [I,C*];
 C07D0491-10 [I,A]; C07D0491-113 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 24 USPATFULL on STN
 AN 2006:87026 USPATFULL
 TI Sustained-release preparations
 IN Saito, Kazuhiro, Osaka-shi, JAPAN
 Futo, Tomomichi, Osaka-shi, JAPAN
 Hoshino, Tetsuo, Osaka-shi, JAPAN
 PA Takeda Pharmaceutical Company Limited (non-U.S. corporation)
 PI US 20060074027 A1 20060406
 AI US 2005-530186 A1 20050209 (10)
 WO 2005-JP1922 20050209
 20050404 PCT 371 date

PRAI JP 2004-34180 20041002

DT Utility
 FS APPLICATION

LN.CNT 1890

INCL INCLM: 514/015.000
 INCLS: 424/468.000

NCL NCLM: 514/015.000
 NCLS: 424/468.000

IC IPCI A61K0038-09 [I,A]; A61K0038-08 [I,C*]; A61K0009-22 [I,A]
 IPCR A61K0038-08 [I,C]; A61K0038-09 [I,A]; A61K0009-22 [I,C];
 A61K0009-22 [I,A]; A61K0009-50 [I,C*]; A61K0009-50 [I,A];
 A61K0009-52 [I,C*]; A61K0009-52 [I,A]; A61K0038-08 [I,A];
 A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0045-00 [I,C*];
 A61K0045-00 [I,A]; A61K0047-34 [I,C*]; A61K0047-34 [I,A];
 A61P0005-00 [I,C*]; A61P0005-02 [I,A]; A61P0013-00 [I,C*];
 A61P0013-08 [I,A]; A61P0015-00 [I,C*]; A61P0015-08 [I,A];
 A61P0035-00 [I,C*]; A61P0035-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 24 USPATFULL on STN
 AN 2006:33911 USPATFULL
 TI Process for the production of implants
 IN Deghenghi, Romano, St. Cergue, SWITZERLAND
 PI US 20060029678 A1 20060209
 AI US 2005-215031 A1 20050829 (11)
 RLI Continuation of Ser. No. WO 2004-GB816, filed on 1 Mar 2004, UNKNOWN

PRAI GB 2003-4726 20030301

DT Utility

FS APPLICATION

LN.CNT 528

INCL INCLM: 424/489.000

INCLS: 514/002.000

NCL NCLM: 424/489.000

NCLS: 514/002.000

IC IPCI A61K0009-14 [I,A]; A61K0038-17 [I,A]

IPCR A61K0009-14 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A];
A61K0009-14 [I,C]; A61K0009-16 [I,C*]; A61K0009-16 [I,A];
A61K0038-04 [I,C*]; A61K0038-04 [I,A]; A61K0038-08 [I,C*];
A61K0038-08 [I,A]; A61K0038-09 [I,A]; A61K0038-10 [I,C*];
A61K0038-10 [I,A]; A61K0038-17 [I,C]; A61K0038-17 [I,A];
A61K0038-22 [I,C*]; A61K0038-22 [I,A]; A61K0038-33 [I,C*];
A61K0038-33 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 24 USPATFULL on STN

AN 2005:318115 USPATFULL

TI Bioimplant formulation

IN Trigg, Timothy Elliot, Warrawee, AUSTRALIA

Walsh, John Desmond, Curl Curl, AUSTRALIA

Rathjen, Deborah Ann, Thornleigh, AUSTRALIA

PA Peptech Limited, North Ryde, AUSTRALIA (non-U.S. corporation)

PI US 20050276854 A1 20051215

AI US 2005-41270 A1 20050125 (11)

RLI Continuation of Ser. No. US 2001-743059, filed on 12 Feb 2001, GRANTED,
Pat. No. US 6913761 A 371 of International Ser. No. WO 1999-AU585, filed
on 20 Jul 1999

PRAI AU 1998-4730 19980720

AU 1998-4731 19980720

AU 1999-324 19990513

DT Utility

FS APPLICATION

LN.CNT 719

INCL INCLM: 424/473.000

INCLS: 514/015.000

NCL NCLM: 424/473.000

NCLS: 514/015.000

IC [7]

ICM A61K038-09

ICS A61K009-64; A61K009-24

IPCI A61K0038-09 [ICM,7]; A61K0038-08 [ICM,7,C*]; A61K0009-64 [ICS,7];

A61K0009-52 [ICS,7,C*]; A61K0009-24 [ICS,7]

IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-70 [I,C*];

A61K0009-70 [I,A]; A61K0031-485 [I,C*]; A61K0031-485 [I,A];

A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61K0045-00 [I,C*];

A61K0045-00 [I,A]; A61K0047-12 [I,C*]; A61K0047-12 [I,A];

A61K0047-14 [I,C*]; A61K0047-14 [I,A]; A61K0047-44 [I,C*];

A61K0047-44 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 24 USPATFULL on STN

AN 2005:248330 USPATFULL

TI GnRh agonist combination drugs

IN Furuya, Shuichi, 13-16-807, Fukaeminamimachi 2-chome, Higashinada-ku,
Kobe-shi, Hyogo, JAPAN

Kusaka, Masami, Hyogo, JAPAN

PI US 20050215528 A1 20050929

AI US 2003-486095 A1 20020808 (10)

WO 2002-JP8130 20020808
20040206 PCT 371 date
PRAI JP 2001-244616 20010810
DT Utility
FS APPLICATION
LN.CNT 2115
INCL INCLM: 514/089.000
INCLS: 514/102.000; 514/319.000; 514/408.000
NCL NCLM: 514/089.000
NCLS: 514/102.000; 514/319.000; 514/408.000
IC [7]
ICM A61K031-675
ICS A61K031-445; A61K031-40
IPCI A61K0031-675 [ICM,7]; A61K0031-445 [ICS,7]; A61K0031-40 [ICS,7]
IPCR A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-52 [I,C*];
A61K0009-52 [I,A]; A61K0031-352 [I,C*]; A61K0031-352 [I,A];
A61K0031-357 [I,C*]; A61K0031-36 [I,A]; A61K0031-4025 [I,C*];
A61K0031-4025 [I,A]; A61K0031-42 [I,C*]; A61K0031-42 [I,A];
A61K0031-4523 [I,C*]; A61K0031-4535 [I,A]; A61K0031-506 [I,C*];
A61K0031-506 [I,A]; A61K0031-58 [I,C*]; A61K0031-58 [I,A];
A61K0031-662 [I,C*]; A61K0031-663 [I,A]; A61K0038-00 [I,C*];
A61K0038-00 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A];
A61P0003-00 [I,C*]; A61P0003-14 [I,A]; A61P0005-00 [I,C*];
A61P0005-06 [I,A]; A61P0009-00 [I,C*]; A61P0009-00 [I,A];
A61P0013-00 [I,C*]; A61P0013-08 [I,A]; A61P0015-00 [I,C*];
A61P0015-00 [I,A]; A61P0015-08 [I,A]; A61P0015-12 [I,A];
A61P0019-00 [I,C*]; A61P0019-00 [I,A]; A61P0019-08 [I,A];
A61P0025-00 [I,C*]; A61P0025-22 [I,A]; A61P0025-28 [I,A];
A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0035-04 [I,A];
A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0007-00 [I,C*];
C07K0007-06 [I,A]; C07K0007-64 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 24 USPATFULL on STN
AN 2005:183966 USPATFULL
TI Remedies for sex hormone-dependent disease
IN Hara, Takahito, Osaka, JAPAN
Kusaka, Masami, Hyogo, JAPAN
PI US 20050159361 A1 20050721
AI US 2003-507044 A1 20030310 (10)
WO 2003-JP2783 20030310
PRAI JP 2002-65734 20020311
DT Utility
FS APPLICATION
LN.CNT 2143
INCL INCLM: 514/016.000
INCLS: 514/017.000; 514/171.000
NCL NCLM: 514/016.000
NCLS: 514/017.000; 514/171.000
IC [7]
ICM A61K038-09
ICS A61K031-58; A61K031-57; A61K031-56
IPCI A61K0038-09 [ICM,7]; A61K0038-08 [ICM,7,C*]; A61K0031-58 [ICS,7];
A61K0031-57 [ICS,7]; A61K0031-56 [ICS,7]
IPCR A61K0031-56 [I,C*]; A61K0031-56 [I,A]; A61K0038-08 [I,C*];
A61K0038-08 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A];
A61P0005-00 [I,C*]; A61P0005-24 [I,A]; A61P0035-00 [I,C*];
A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 24 USPATFULL on STN

AN 2005:167632 USPATFULL
 TI Bioimplant formulation
 IN Trigg, Timothy Elliot, Warrawee, AUSTRALIA
 Walsh, John Desmond, Curl Curl, AUSTRALIA
 Rathjen, Deborah Ann, Thornleigh, AUSTRALIA
 PA Peptech Limited, New South Wales, AUSTRALIA (non-U.S. corporation)
 PI US 6913761 B1 20050705
 WO 2000004897 20000203
 AI US 2001-743059 19990720 (9)
 WO 1999-AU585 19990720
 20010104 PCT 371 date
 PRAI AU 1998-4730 19980720
 AU 2001-4731 19980720
 AU 2001-324 19990513
 DT Utility
 FS GRANTED
 LN.CNT 749
 INCL INCLM: 424/423.000
 INCLS: 424/450.000; 514/012.000; 514/014.000; 514/015.000; 514/016.000;
 514/017.000; 514/018.000; 514/019.000; 514/513.000; 514/515.000;
 530/328.000
 NCL NCLM: 424/423.000
 NCLS: 424/450.000; 514/012.000; 514/014.000; 514/015.000; 514/016.000;
 514/017.000; 514/018.000; 514/019.000; 514/513.000; 514/515.000;
 530/328.000
 IC [7]
 ICM A61F002-02
 ICS A61K038-20; A61K031-21; A61K038-04
 IPCI A61F0002-02 [ICM,7]; A61K0038-20 [ICS,7]; A61K0031-21 [ICS,7];
 A61K0038-04 [ICS,7]
 IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-70 [I,C*];
 A61K0009-70 [I,A]; A61K0031-485 [I,C*]; A61K0031-485 [I,A];
 A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61K0045-00 [I,C*];
 A61K0045-00 [I,A]; A61K0047-12 [I,C*]; A61K0047-12 [I,A];
 A61K0047-14 [I,C*]; A61K0047-14 [I,A]; A61K0047-44 [I,C*];
 A61K0047-44 [I,A]
 EXF 424/423; 424/450; 514/12; 514/14; 514/15; 514/16; 514/17; 514/18;
 514/19; 514/513; 514/514; 514/515; 530/328
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 24 USPATFULL on STN
 AN 2004:233758 USPATFULL
 TI Sustained peptide-release formulation
 IN Trigg, Timothy Elliot, Warrawee, AUSTRALIA
 Walsh, John Desmond, Curl Curl, AUSTRALIA
 Schober, Paul Adam, Beacon Hill, AUSTRALIA
 PA Peptech Limited, North Ryde, AUSTRALIA (non-U.S. corporation)
 PI US 20040180832 A1 20040916
 US 7309689 B2 20071218
 AI US 2004-808504 A1 20040325 (10)
 RLI Division of Ser. No. US 2001-991714, filed on 26 Nov 2001, PENDING
 Continuation of Ser. No. US 1999-242635, filed on 19 Feb 1999, GRANTED,
 Pat. No. US 6337318
 PRAI AU 1996-2035 19960830
 AU 1996-4107 19961206
 WO 1997-AU560 19970901
 DT Utility
 FS APPLICATION
 LN.CNT 519
 INCL INCLM: 514/012.000
 INCLS: 514/078.000

NCL NCLM: 514/002.000; 514/012.000
NCLS: 514/015.000; 514/078.000
IC [7]
ICM A61K038-25
ICS A61K031-685
IPCI A61K0038-25 [ICM,7]; A61K0031-685 [ICS,7]; A61K0031-683
[ICS,7,C*]
IPCI-2 A61K0038-00 [I,A]
IPCR A61K0038-00 [I,C]; A61K0038-00 [I,A]; A61K0009-00 [I,C*];
A61K0009-00 [I,A]; A61K0009-70 [I,C*]; A61K0009-70 [I,A];
A61K0038-08 [I,C*]; A61K0038-09 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 24 USPATFULL on STN
AN 2004:57931 USPATFULL
TI Combination therapy for estrogen-dependent disorders
IN Purandare, Dinesh, Branchburg, NJ, UNITED STATES
PI US 20040043938 A1 20040304
AI US 2003-416844 A1 20030912 (10)
WO 2001-US43847 20011106
DT Utility
FS APPLICATION
LN.CNT 449
INCL INCLM: 514/016.000
INCLS: 514/017.000; 514/171.000; 514/383.000; 514/397.000
NCL NCLM: 514/016.000
NCLS: 514/017.000; 514/171.000; 514/383.000; 514/397.000
IC [7]
ICM A61K038-09
ICS A61K031-56; A61K031-4196; A61K031-4178
IPCI A61K0038-09 [ICM,7]; A61K0038-08 [ICM,7,C*]; A61K0031-56 [ICS,7];
A61K0031-4196 [ICS,7]; A61K0031-4178 [ICS,7]; A61K0031-4164
[ICS,7,C*]
IPCR A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C*];
A61K0031-4196 [I,A]; A61K0031-56 [I,C*]; A61K0031-56 [I,A];
A61K0038-08 [I,C*]; A61K0038-09 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 24 USPATFULL on STN
AN 2003:207842 USPATFULL
TI Methods for slowing senescence and treating and preventing diseases
associated with senescence
IN Bowen, Richard L., Raleigh, NC, UNITED STATES
PA Voyager Pharmaceutical Corporation, Raleigh, NC (U.S. corporation)
PI US 20030144203 A1 20030731
AI US 2002-321579 A1 20021218 (10)
PRAI US 2001-340502P 20011219 (60)
US 2002-385577P 20020605 (60)
US 2002-369857P 20020405 (60)
US 2002-385576P 20020605 (60)
US 2002-383624P 20020529 (60)
US 2002-385560P 20020605 (60)
US 2002-385559P 20020605 (60)
US 2002-385561P 20020605 (60)
US 2002-385575P 20020605 (60)
DT Utility
FS APPLICATION
LN.CNT 2605
INCL INCLM: 514/012.000
INCLS: 514/015.000; 514/016.000; 514/017.000
NCL NCLM: 514/012.000

NCLS: 514/015.000; 514/016.000; 514/017.000
IC [7]
ICM A61K038-24
ICS A61K038-09
IPCI A61K0038-24 [ICM,7]; A61K0038-09 [ICS,7]; A61K0038-08 [ICS,7,C*]
IPCR A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-045 [I,C*];
A61K0031-07 [I,A]; A61K0031-165 [I,C*]; A61K0031-165 [I,A];
A61K0031-17 [I,C*]; A61K0031-17 [I,A]; A61K0031-337 [I,C*];
A61K0031-337 [I,A]; A61K0038-08 [I,C*]; A61K0038-09 [I,A];
A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0045-00 [I,C*];
A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 24 USPATFULL on STN
AN 2002:99419 USPATFULL
TI Sustained peptide-release formulation
IN Trigg, Timothy Elliot, Warrawee, AUSTRALIA
Walsh, John Desmond, Curl Curl, AUSTRALIA
Schober, Paul Adam, Beacon Hill, AUSTRALIA
PA Peptech Limited (non-U.S. corporation)
PI US 20020052320 A1 20020502
US 6777386 B2 20040817
AI US 2001-991714 A1 20011126 (9)
RLI Continuation of Ser. No. US 1999-242635, filed on 19 Feb 1999, PENDING
PRAI AU 1996-2035 19960830
AU 1996-4107 19961206
WO 1997-AU560 19970901
DT Utility
FS APPLICATION
LN.CNT 517
INCL INCLM: 514/012.000
NCL NCLM: 514/002.000; 514/012.000
NCLS: 514/015.000
IC [7]
ICM A61K038-18
IPCI A61K0038-18 [ICM,7]
IPCI-2 A61K0038-00 [ICM,7]
IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-70 [I,C*];
A61K0009-70 [I,A]; A61K0038-08 [I,C*]; A61K0038-09 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 24 USPATFULL on STN
AN 2002:5988 USPATFULL
TI Sustained GnRH peptide-release formulation
IN Trigg, Timothy Elliot, Warrawee, AUSTRALIA
Walsh, John Desmond, Curl Curl, AUSTRALIA
Schober, Paul Adam, Beacon Hill, AUSTRALIA
PA Peptech, Ltd., New South Wales, AUSTRALIA (non-U.S. corporation)
PI US 6337318 B1 20020108
WO 9808533 19980305
AI US 1999-242635 19990219 (9)
WO 1997-AU560 19970901
19990219 PCT 371 date
PRAI AU 1996-2035 19960830
AU 1996-4107 19961206
DT Utility
FS GRANTED
LN.CNT 533
INCL INCLM: 514/015.000
INCLS: 530/328.000; 424/422.000; 424/428.000; 514/008.000; 514/012.000;
514/014.000; 514/016.000; 514/017.000; 514/018.000; 514/019.000;

514/513.000; 514/515.000
NCL NCLM: 514/015.000
NCLS: 424/422.000; 424/428.000; 514/008.000; 514/012.000; 514/014.000;
514/016.000; 514/017.000; 514/018.000; 514/019.000; 514/513.000;
514/515.000; 530/328.000
IC [7]
ICM A61K038-08
ICS A61K038-09
IPCI A61K0038-08 [ICM,7]; A61K0038-09 [ICS,7]; A61K0038-08 [ICS,7,C*]
IPCR A61K0047-14 [I,C*]; A61K0047-14 [I,A]; A61K0009-00 [I,C*];
A61K0009-00 [I,A]; A61K0009-70 [I,C*]; A61K0009-70 [I,A];
A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61K0038-08 [I,C*];
A61K0038-09 [I,A]; A61K0038-24 [I,C*]; A61K0038-24 [I,A];
A61P0013-00 [I,C*]; A61P0013-08 [I,A]; A61P0015-00 [I,C*];
A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-00 [I,A];
A61P0027-00 [I,C*]; A61P0027-16 [I,A]; A61P0035-00 [I,C*];
A61P0035-00 [I,A]
EXF 514/8; 514/12; 514/14-19; 514/513; 514/515; 424/422; 424/428; 530/328
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 24 USPATFULL on STN
AN 2001:75365 USPATFULL
TI Non-aqueous polar aprotic peptide formulations
IN Stevenson, Cynthia L., Mountain View, CA, United States
Prestrelski, Steven J., Mountain View, CA, United States
PA ALZA Corporation, Mountain View, CA, United States (U.S. corporation)
PI US 6235712 B1 20010522
AI US 2000-514951 20000228 (9)
RLI Division of Ser. No. US 1999-293839, filed on 19 Apr 1999, now patented,
Pat. No. US 6124261 Continuation of Ser. No. US 1997-874233, filed on 13
Jun 1997, now patented, Pat. No. US 5932547
DT Utility
FS Granted
LN.CNT 785
INCL INCLM: 514/011.000
INCLS: 514/012.000; 530/300.000; 530/313.000; 530/317.000; 530/324.000
NCL NCLM: 514/011.000
NCLS: 514/012.000; 530/300.000; 530/313.000; 530/317.000; 530/324.000
IC [7]
ICM A61K038-00
ICS C07K005-00; C07K007-00
IPCI A61K0038-00 [ICM,7]; C07K0005-00 [ICS,7]; C07K0007-00 [ICS,7]
IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0038-08 [I,C*];
A61K0038-09 [I,A]; A61K0047-16 [I,C*]; A61K0047-18 [I,A];
A61K0047-20 [I,A]; A61K0047-20 [I,C*]; C07K0007-00 [I,C*];
C07K0007-23 [I,A]
EXF 514/11; 514/12; 530/300; 530/313; 530/317; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 19 OF 24 USPATFULL on STN
AN 2000:128294 USPATFULL
TI Non-aqueous polar aprotic peptide formulations
IN Stevenson, Cynthia L., Mountain View, CA, United States
Prestrelski, Steven J., Mountain View, CA, United States
PA ALZA Corporation, Mt. View, CA, United States (U.S. corporation)
PI US 6124261 20000926
AI US 1999-293839 19990419 (9)
RLI Continuation of Ser. No. US 1997-874233, filed on 13 Jun 1997
DT Utility
FS Granted
LN.CNT 828

INCL INCLM: 514/012.000
 INCLS: 514/015.000; 530/313.000; 530/328.000; 424/600.000
 NCL NCLM: 514/012.000
 NCLS: 424/600.000; 514/015.000; 530/313.000; 530/328.000
 IC [7]
 ICM A61K038-00
 ICS A61K038-24; C07K005-00; C07K007-00
 IPCI A61K0038-00 [ICM, 7]; A61K0038-24 [ICS, 7]; C07K0005-00 [ICS, 7];
 C07K0007-00 [ICS, 7]
 IPCR A61K0038-00 [N, A]; A61K0038-00 [N, C*]; A61K0038-08 [I, C*];
 A61K0038-09 [I, A]; A61K0047-16 [I, C*]; A61K0047-18 [I, A];
 A61K0047-20 [I, A]; A61K0047-20 [I, C*]; C07K0007-00 [I, C*];
 C07K0007-23 [I, A]
 EXF 514/12; 514/15; 424/600; 530/313; 530/328
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 20 OF 24 USPATFULL on STN
 AN 2000:67441 USPATFULL
 TI Aqueous formulations of peptides
 IN Stevenson, Cynthia L., Mountain View, CA, United States
 Tao, Sally A., San Jose, CA, United States
 Prestrelski, Steven J., Mountain View, CA, United States
 Eckenhoff, deceased, James B., late of Los Altos, CA, United States by
 Bonnie J. Eckenhoff, executrix
 Wright, Jeremy C., Los Altos, CA, United States
 Leonard, Jr., John J., Cupertino, CA, United States
 PA Alza Corporation, CA, United States (U.S. corporation)
 PI US 6068850 20000530
 AI US 1999-248286 19990211 (9)
 RLI Continuation of Ser. No. US 1997-874694, filed on 13 Jun 1997, now
 patented, Pat. No. US 5916582
 DT Utility
 FS Granted
 LN.CNT 858
 INCL INCLM: 424/423.000
 NCL NCLM: 424/423.000
 IC [7]
 ICM A61F002-02
 IPCI A61F0002-02 [ICM, 7]
 IPCR A61K0009-00 [N, A]; A61K0009-00 [N, C*]; A61K0009-08 [N, A];
 A61K0009-08 [N, C*]; A61K0038-08 [I, C*]; A61K0038-09 [I, A];
 A61K0047-20 [N, A]; A61K0047-20 [N, C*]
 EXF 424/423

L5 ANSWER 21 OF 24 USPATFULL on STN
 AN 2000:64845 USPATFULL
 TI Non-aqueous protic peptide formulations
 IN Stevenson, Cynthia L., Mountain View, CA, United States
 Tao, Sally A., San Jose, CA, United States
 Prestrelski, Steven J., Mountain View, CA, United States
 Eckenhoff, James B., Los Altos, CA, United States
 Wright, Jeremy C., Los Altos, CA, United States
 Leonard, Jr., John J., Cupertino, CA, United States
 PA Alza Corporation, Mt. View, CA, United States (U.S. corporation)
 PI US 6066619 20000523
 AI US 1999-293172 19990416 (9)
 RLI Continuation of Ser. No. US 1997-874680, filed on 13 Jun 1997
 DT Utility
 FS Granted
 LN.CNT 897
 INCL INCLM: 514/012.000

INCLS: 514/015.000; 530/313.000; 530/328.000
NCL NCLM: 514/012.000
NCLS: 514/015.000; 530/313.000; 530/328.000
IC [7]
ICM A61K038-00
ICS C07K005-00; C07K007-00
IPCI A61K0038-00 [ICM,7]; C07K0005-00 [ICS,7]; C07K0007-00 [ICS,7]
IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0038-08 [I,C*];
A61K0038-09 [I,A]; A61K0047-10 [I,A]; A61K0047-10 [I,C*];
A61K0047-12 [N,A]; A61K0047-12 [N,C*]; A61K0047-16 [N,C*];
A61K0047-18 [N,A]; A61K0047-20 [N,A]; A61K0047-20 [N,C*];
C07K0014-435 [I,C*]; C07K0014-71 [I,A]
EXF 514/12; 514/15; 530/313; 530/328; 424/600; 424/40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 22 OF 24 USPATFULL on STN
AN 1999:141896 USPATFULL
TI Non-aqueous protic peptide formulations
IN Stevenson, Cynthia L., Mountain View, CA, United States
Tao, Sally A., San Jose, CA, United States
Prestrelski, Steven J., Mountain View, CA, United States
Eckenhoff, deceased, James B., late of Los Altos, CA, United States by
Bonnie J. Eckenhoff, executrix
Wright, Jeremy C., Los Altos, CA, United States
Leonard, Jr., John J., Cupertino, CA, United States
PA Alza Corporation, Palo Alto, CA, United States (U.S. corporation)
PI US 5981489 19991109
AI US 1997-874680 19970613 (8)
DT Utility
FS Granted
LN.CNT 978
INCL INCLM: 514/015.000
INCLS: 530/313.000; 530/328.000
NCL NCLM: 514/015.000
NCLS: 530/313.000; 530/328.000
IC [6]
ICM A61K038-00
ICS C07K005-00; C07K007-00
IPCI A61K0038-00 [ICM,6]; C07K0005-00 [ICS,6]; C07K0007-00 [ICS,6]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0038-08 [I,C*];
A61K0038-09 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A];
A61K0047-12 [N,C*]; A61K0047-12 [N,A]; A61K0047-16 [N,C*];
A61K0047-18 [N,A]; A61K0047-20 [N,C*]; A61K0047-20 [N,A];
C07K0014-435 [I,C*]; C07K0014-71 [I,A]
EXF 514/15; 514/12; 530/313; 530/328
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 24 USPATFULL on STN
AN 1999:89123 USPATFULL
TI Non-aqueous polar aprotic peptide formulations
IN Stevenson, Cynthia L., Mountain View, CA, United States
Prestrelski, Steven J., Mountain View, CA, United States
PA ALZA Corporation, Palo Alto, CA, United States (U.S. corporation)
PI US 5932547 19990803
AI US 1997-874233 19970613 (8)
DT Utility
FS Granted
LN.CNT 817
INCL INCLM: 514/015.000
INCLS: 530/313.000; 530/328.000
NCL NCLM: 514/015.000

NCLS: 530/313.000; 530/328.000
 IC [6]
 ICM A61K038-00
 ICS C07K005-00; C07K007-00
 IPCI A61K0038-00 [ICM,6]; C07K0005-00 [ICS,6]; C07K0007-00 [ICS,6]
 IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0038-08 [I,C*];
 A61K0038-09 [I,A]; A61K0047-16 [I,C*]; A61K0047-18 [I,A];
 A61K0047-20 [I,C*]; A61K0047-20 [I,A]; C07K0007-00 [I,C*];
 C07K0007-23 [I,A]
 EXF 530/328; 530/313; 514/15
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

 L5 ANSWER 24 OF 24 USPATFULL on STN
 AN 1999:72277 USPATFULL
 TI Aqueous formulations of peptides
 IN Stevenson, Cynthia L., Mountain View, CA, United States
 Tao, Sally A., San Jose, CA, United States
 Prestrelski, Steven J., Mountain View, CA, United States
 Eckenhoff, deceased, James B., late of Los Altos, CA, United States by
 Bonnie J. Eckenhoff
 Wright, Jeremy C., Los Altos, CA, United States
 Leonard, Jr., John J., Cupertino, CA, United States
 PA ALZA Corporation, Palo Alto, CA, United States (U.S. corporation)
 PI US 5916582 19990629
 AI US 1997-874694 19970613 (8)
 DT Utility
 FS Granted
 LN.CNT 819
 INCL INCLM: 424/423.000
 INCLS: 424/426.000
 NCL NCLM: 424/423.000
 NCLS: 424/426.000
 IC [6]
 ICM A61F002-02
 IPCI A61F0002-02 [ICM,6]
 IPCR A61K0009-00 [N,C*]; A61K0009-00 [N,A]; A61K0009-08 [N,C*];
 A61K0009-08 [N,A]; A61K0038-08 [I,C*]; A61K0038-09 [I,A];
 A61K0047-20 [N,C*]; A61K0047-20 [N,A]
 EXF 424/423; 424/426

=>